抑制谷氨酰胺酶1减少糖酵解并改善MRL/lpr小鼠狼疮样疾病及实验性自身免疫性脑脊髓炎
该研究在MRL/lpr小鼠、SLE患者naive CD4+ T细胞及Gls1条件性敲除小鼠中探讨抑制谷氨酰胺分解对SLE的治疗作用及机制。BPTES抑制Gls1可以Th17依赖方式改善小鼠自身免疫病理,降低SLE患者Th17分化(P < 0.05),并减少糖酵解和HIF-1α蛋白表达。
要点
- Gls1抑制剂BPTES以Th17依赖方式改善MRL/lpr小鼠狼疮样疾病。
- SLE患者T细胞经BPTES处理后Th17分化降低(P < 0.05)。
- Gls1抑制通过降低HIF-1α蛋白减少Th17细胞糖酵解。
核心结论
- 抑制谷氨酰胺分解是SLE及Th17相关自身免疫病的潜在新治疗策略。
- 机制上,抑制谷氨酰胺分解通过降低Th17细胞HIF-1α蛋白影响糖酵解通路。
研究设计与样本
- MRL/lpr小鼠分别接受BPTES或溶剂对照治疗并评估疾病活动。
- SLE患者naive CD4+ T细胞在Th17极化条件下经BPTES或溶剂对照培养。
- 使用新构建的Gls1条件性敲除小鼠检测体外Th17分化并诱导EAE。
- 用细胞外通量分析仪检测谷氨酰胺分解和糖酵解,Western blotting检测HIF-1α表达。
主要发现
- BPTES治疗MRL/lpr小鼠以Th17依赖方式改善自身免疫病理。
- SLE患者T细胞经BPTES处理后Th17分化降低(P < 0.05)。
- Gls1条件性敲除小鼠中体外Th17分化(P < 0.05)和EAE发生均依赖Gls1。
- 抑制Gls1降低糖酵解及诱导糖酵解的HIF-1α蛋白表达。
临床怎么用
- 提示靶向Gls1或谷氨酰胺分解可能用于SLE及Th17相关自身免疫病的治疗探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glutaminase 1 (Gls1) is the first enzyme in glutaminolysis. The selective Gls1 inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) suppresses Th17 development and ameliorates experimental autoimmune encephalomyelitis (EAE). The present study was undertaken to investigate whether inhibition of glutaminolysis is beneficial for the treatment of systemic lupus erythematosus (SLE), and the involved mechanisms. METHODS: MRL/lpr mice were treated with BPTES or vehicle control, and disease activity was examined. Then naive CD4+ T cells from patients with SLE were cultured under Th17-polarizing conditions with BPTES or vehicle. Furthermore, using newly generated Gls1 conditional-knockout mice, in vitro Th17 differentiation was examined, and EAE was induced in the mice. Glutaminolysis and glycolysis were measured with an extracellular flux analyzer. The expression of hypoxia-inducible factor 1α (HIF-1α) was examined by Western blotting. RESULTS: Treatment of MRL/lpr mice with BPTES improved autoimmune pathology in a Th17-dependent manner. T cells from patients with SLE treated with BPTES displayed decreased Th17 differentiation (P < 0.05). Using the conditional-knockout mice, we demonstrated that both in vitro Th17 differentiation (P < 0.05) and the development of EAE were dependent on Gls1. Gls1 inhibition reduced glycolysis and the expression of HIF-1α protein, which induces glycolysis. CONCLUSION: We demonstrated that inhibition of glutaminolysis represents a potential new treatment strategy for patients with SLE and Th17-related autoimmune diseases. Mechanistically, we have shown that inhibition of glutaminolysis affects the glycolysis pathway by reducing HIF-1α protein in Th17 cells.
引用
- Kono M, Yoshida N, Maeda K, et al. Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus-like Disease in MRL/lpr Mice and Experimental Autoimmune Encephalomyelitis. Arthritis Rheumatol. 2019. PMID: 31233276. doi:10.1002/art.41019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。